- Home
- WRN vs ASMB Comparison
WRN vs ASMB Comparison
Compare WRN & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WRN | ASMB |
|---|---|---|
| Founded | 2006 | 2005 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 493.1M | 512.1M |
| IPO Year | 2006 | 2010 |
Fundamental Metrics
Financial Performance| Metric | WRN | ASMB |
|---|---|---|
| Price | $1.72 | $20.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $5.50 | ★ $52.00 |
| AVG Volume (30 Days) | ★ 1.1M | 202.1K |
| Earning Date | 11-05-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.76 | $19.94 |
| 52 Week High | $4.26 | $39.71 |
Technical Indicators
Market Signals| Indicator | WRN | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 23.93 | 31.31 |
| Support Level | N/A | N/A |
| Resistance Level | $2.59 | $30.36 |
| Average True Range (ATR) | 0.08 | 1.10 |
| MACD | -0.02 | 0.10 |
| Stochastic Oscillator | 1.94 | 7.07 |
Price Performance
Historical ComparisonAbout WRN Western Copper and Gold Corporation
Western Copper & Gold Corp is a Canada-based exploration-stage company. The company is engaged in the exploration and development of the Casino mineral property located in Yukon, Canada (the Casino Project). The Casino can deliver the critical minerals necessary for the energy transition while serving as an engine for long-term economic growth and prosperity in the North.
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.